Company intelligence / Profile preview

Qureight

Cambridge, England, United Kingdom

Ownership: Private
Development stage: Other

Overview

Qureight’s AI lung imaging platform is being used as image-based endpoints in global Phase 2 and 3 clinical trials for IPF and PH; the company collaborates on data curation and analytics with top pharma and healthcare organizations but does not have its own drug programs

Therapeutic areas: OncologyPulmonologyCardiovascular
Modalities: DeviceDiagnostic
Industry: Digital Health Medical Devices

Partnerships

AstraZenecaVicore PharmaClarioMultiple NHS Trusts

Beyond the preview

Go deeper on Qureight.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Qureight.

Explore the full profile